TrialImmunoHorizons2025

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

Johannes F Scheid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.